Q-omics provides the consensus-scored FIRRE profile across patient tissues and cancer cell-line models. FIRRE expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FIRRE is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, FIRRE RNA expression shows 17,003 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, COAD, and TGCT as cancer lineages where FIRRE shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FIRRE — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FIRRE survival associations across molecular data types. FIRRE RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FIRRE RNA expression–survival associations across cancer types. High FIRRE expression shows unfavorable associations in KIRC, KIRP, UCEC, PAAD, COAD and KICH. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FIRRE RNA expression.
This table summarizes FIRRE tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FIRRE. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FIRRE shows higher tumor expression in COAD, HNSC, KIRC, BLCA, STAD and LUSC. The COAD box plot shows higher FIRRE RNA expression in tumor versus normal tissue (log2 FC = +1.139, t-test p < 0.001).
This table shows molecular features associated with FIRRE in patient tissues and cancer cell lines. In patient samples, FIRRE shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
